NRX Pharmaceuticals CEO gets 150K-unit stock grant

Vesting is spread across three annual dates and requires continued service through each vesting date.

Available on EDGAR 11/04/2026 - 05:52 PM EST Accepted by SEC EDGAR 11/04/2026 - 05:51 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NRX Pharmaceuticals, Inc. CEO and Chairman Jonathan C. Javitt received a grant of 150,000 restricted stock units on July 28, 2026. Each unit represents a contingent right to receive one share of common stock for no consideration at vesting. The units vest in three equal annual installments on July 28, 2027, July 28, 2028 and July 28, 2029, subject to his continued service through each date. His reported resulting position is 150,000 restricted stock units.

Insider Trade Summary

Grant/Award: 150,000 shares

Grant/Award 1 txn

Insider Javitt Jonathan C

Role CEO and Chairman

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1, F2	150,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 150,000 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSUs') represents a contingent right to receive one share of the Issuer's common stock at the time of vesting for no consideration.
2. F2. The restricted stock units were granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended. The RSUs vest in three equal annual installments on July 28, 2027, July 28, 2028 and July 28, 2029, subject to the reporting person's continued service through each vesting date.

Key Figures

Restricted stock units granted: 150,000 units Underlying common shares: 150,000 shares Vesting installments: 3 equal annual installments +2 more

5 metrics

Restricted stock units granted 150,000 units Granted July 28, 2026

Underlying common shares 150,000 shares One share per unit at vesting

Vesting installments 3 equal annual installments Subject to continued service through each vesting date

Vesting dates July 28, 2027; July 28, 2028; July 28, 2029 Annual installments

Resulting restricted stock unit position 150,000 units Following the reported grant

Key Terms

restricted stock unit, contingent right, vesting

3 terms

restricted stock unit financial

"Each restricted stock unit represents a contingent right"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"a contingent right to receive one share"

vesting financial

"at the time of vesting for no consideration"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NRXP restricted stock units did Jonathan C. Javitt receive?

Jonathan C. Javitt, NRX Pharmaceuticals, Inc.'s CEO and Chairman, received 150,000 restricted stock units on July 28, 2026. Each unit represents a contingent right to one common share at vesting for no consideration.

What plan governs Jonathan C. Javitt's NRXP restricted stock units?

The restricted stock units were granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Javitt Jonathan C

(Last) (First) (Middle)

C/O NRX PHARMACEUTICALS, INC.

1201 ORANGE STREET, SUITE 600

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NRX Pharmaceuticals, Inc. [ NRXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	07/28/2026		A		150,000		(2)	(2)	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSUs') represents a contingent right to receive one share of the Issuer's common stock at the time of vesting for no consideration.

2. The restricted stock units were granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended. The RSUs vest in three equal annual installments on July 28, 2027, July 28, 2028 and July 28, 2029, subject to the reporting person's continued service through each vesting date.

	/s/ Jonathan Javitt	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)